Myelodysplastic syndrome/Acute myeloid leukemia
Conditions
Interventions
experimental group:Azacitidine: 35 mg-75mg/m2 Subcutaneous injection one time/day, consecutively 7 days in a month x 12 times or three months until the MRD becomes negative
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients between the ages of 18-60, male and female are not limited; 2. Patients without severe gravity, lung, liver and kidney diseases; 3. Patients with high-risk MDS or AML who received allogeneic transplantation for one month; 4. MRD positive patients were reexamined at any time after high-risk MDS or AML transplantation; 5. Each condition should meet the basic normal blood routine; 6. Patients who are able to understand and willing to sign the informed consent of this trial.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with uncontrolled heart failure, unstable angina, arrhythmia or mental disease; 3. Patients with uncontrollable infectious diseases; 4. HIV infected patients; 5. Patients with stage 3 or above chronic kidney disease; 6. Patients with recurrence of basic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission state of bone marrow;remission state of hematology ;disappear of extramedullary invasion;event-free survival;overall survival;cumulative disease rate of relapse ; | — |
Secondary
| Measure | Time frame |
|---|---|
| early mortality rate ; | — |
Countries
China
Contacts
Public ContactWang Li
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed